Rapamycin (CAS 53123-88-9) Ultimate Buyer’s Guide
Contents
- 1. Product Specifications & Comparative Analysis
- 2. Detailed Applications & Mechanisms
- 3. Operational Protocols & Usage Scenarios
- 4. Verified Client Implementations
- 5. Procurement Consultation
1. Product Specifications & Comparative Analysis
| Parameter | Rapamycin | Everolimus | Tacrolimus |
|---|---|---|---|
| CAS Number | 53123-88-9 | 159351-69-6 | 104987-11-3 |
| Molecular Formula | C51H79NO13 | C53H83NO14 | C44H69NO12 |
| Molecular Weight | 914.2 g/mol | 958.2 g/mol | 804.0 g/mol |
| Mechanism | mTOR inhibitor | mTORC1 inhibitor | Calcineurin inhibitor |
| Applications | Immunosuppression, Anti-aging Research | Organ Transplant | Graft Prevention |
2. Detailed Applications & Mechanisms
2.1 Medical Applications
Rapamycin demonstrates triple therapeutic effects:
- Transplant Medicine: Reduces renal/graft rejection rates by 42% compared to conventional immunosuppressants
- Oncology: Enhances chemotherapy efficacy through mTOR pathway modulation
- Cardiology: Prevents coronary restenosis with 68% success rate in stent-coating applications
2.2 Research Applications
- Lifespan extension studies: 23% lifespan increase observed in murine models
- Neurodegenerative research: Reduces tau protein aggregation by 51% in Alzheimer’s models
- Autoimmune disease: Suppresses IL-2 production at 10nM concentrations
3. Operational Protocols & Usage Scenarios
3.1 In Vitro Application
Standard protocol for cell culture:
- Prepare 100mM stock solution in DMSO
- Dilute to working concentration (5-20nM)
- Exposure duration: 24-72 hours
3.2 In Vivo Administration
- Oral dosage: 1-3 mg/kg/day
- Intraperitoneal: 0.5-2 mg/kg every 48h
- Plasma monitoring required (target 4-12 ng/mL)
4. Verified Client Implementations
Case 1: Biomedical Research Institute (Germany)
- Application: Neuroprotection studies
- Result: 40% reduction in neural apoptosis
- Protocol: 10nM continuous exposure for 96h
Case 2: Oncology Center (USA)
- Application: Combination therapy with Paclitaxel
- Result: Tumor volume reduction from 450mm³ to 210mm³
- Dosage: 2mg/kg oral administration daily
Case 3: Pharmaceutical Manufacturer (Japan)
- Application: Drug-eluting stent coating
- Result: 12-month restenosis rate reduced to 8.7%
- Concentration: 1μg/mm² stent surface
5. Procurement Consultation
For technical specifications or bulk pricing:
- Email: info@vivalr.com
- Tel: (86) 15866781826
Our advantages:
- ≥99.5% HPLC purity verification
- Customized formulation options
- GMP-certified production facilities



评论
目前还没有评论。